I-Mab Sponsored ADR (0VY)

Overview

NovaBridge Biosciences American Depositary Shares represent ownership in NovaBridge Biosciences, a biotechnology company founded in 2020 and headquartered in Shanghai, China. This innovative firm specializes in developing advanced precision therapies primarily tailored for oncology and immunology indications. With a commitment to addressing unmet medical needs, NovaBridge focuses on creating groundbreaking treatment options for patients suffering from difficult-to-treat cancers and autoimmune diseases. The company operates by leveraging next-generation technologies and platforms, including proprietary linker-payload systems and tumor-targeted delivery methods, which enhance therapeutic efficacy and minimize toxicity. Through a combination of discovery, preclinical development, and clinical-stage programs, NovaBridge aims to expedite the advancement of its therapeutic pipeline while actively partnering with global pharmaceutical companies to accelerate innovation in the biotechnology sector.

Products and Services

• Antibody-Drug Conjugates (ADCs): NovaBridge is at the forefront of developing next-generation ADCs, which combine antibodies with cytotoxic drugs to deliver targeted therapy directly to cancer cells. This method enhances the effectiveness of cancer treatment while reducing systemic toxicity.
• Bispecific Antibodies: These innovative therapeutics are designed to engage two different antigens simultaneously, potentially leading to more effective treatment strategies for complex diseases such as cancer and autoimmune disorders.
• Protein Degraders: The company is pioneering research in protein degradation technologies aimed at selectively targeting and eliminating disease-causing proteins within cells, which provides a novel therapeutic approach for treating various cancers and immune-related diseases.
• Linker-Payload Technologies: NovaBridge employs proprietary linker-payload systems that enhance the delivery and efficacy of its therapeutics. This technology is crucial in ensuring that the therapeutic compounds reach their intended targets with minimal side effects.
• Tumor-Targeted Delivery Systems: By utilizing advanced delivery systems, NovaBridge aims to improve the localization of therapies at the tumor site, thereby maximizing treatment effectiveness and further reducing overall toxicity for patients.